How should we treat acinetobacter pneumonia?
Amaya-Villar R, Garnacho-Montero J.
Curr Opin Crit Care. 2019 Oct;25(5):465-472. doi: 10.1097/MCC.0000000000000649.
Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy.
Vazquez Guillamet C, Kollef MH.
Clin Infect Dis. 2018 Oct 15;67(9):1455-1462. doi: 10.1093/cid/ciy375.
Sulbactam-durlobactam for Acinetobacter pneumonia.
Mushtaq A, Anand Raman A.
Lancet Infect Dis. 2023 Aug;23(8):e283. doi: 10.1016/S1473-3099(23)00450-4.
Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
[No authors listed]
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-190. doi: 10.58347/tml.2023.1690c.
Nosocomial Acinetobacter pneumonia.
Luna CM, Aruj PK.
Respirology. 2007 Nov;12(6):787-91. doi: 10.1111/j.1440-1843.2007.01147.x.
Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Franzone JP, Mackow NA, van Duin D.
Curr Opin Infect Dis. 2024 Apr 1;37(2):137-143. doi: 10.1097/QCO.0000000000001001. Epub 2024 Jan 3.
Acinetobacter pneumonia: a review.
Hartzell JD, Kim AS, Kortepeter MG, Moran KA.
MedGenMed. 2007 Jul 5;9(3):4.
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?
Jean SS, Liu CY, Huang TY, Lai CC, Liu IM, Hsieh PC, Hsueh PR.
Expert Rev Anti Infect Ther. 2024 Dec;22(12):1171-1187. doi: 10.1080/14787210.2024.2412637. Epub 2024 Oct 9.
Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia.
Shein AMS, Hongsing P, Smith OK, Phattharapornjaroen P, Miyanaga K, Cui L, Ishikawa H, Amarasiri M, Monk PN, Kicic A, Chatsuwan T, Pletzer D, Higgins PG, Abe S, Wannigama DL.
Crit Rev Microbiol. 2025 May;51(3):441-462. doi: 10.1080/1040841X.2024.2369948. Epub 2024 Jul 1.
[Acinetobacter spp].
Matsunaga N.
Nihon Rinsho. 2012 Feb;70(2):236-42.
